"Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin." Clinical infectious diseases 54.11 (2012): 1642-1651
Beta-3 adrenergic receptor knockout mice are unresponsive to the lipolytic effects of AOD9604
The peptides in this category also influence integrin-FAK signaling and eNOS-driven nitric oxide releasecritical in both revascularization and immune modulation
6-month duration may not capture full benefit
Known Side Effects Reported side effects are generally mild and infrequent: Injection site reactions: temporary redness, mild swelling, or tenderness Nausea: occasionally reported, usually mild and transient Dizziness: rare, typically with first doses Fatigue: some users report temporary tiredness Headache: infrequent, usually resolves quickly These effects typically diminish with continued use and rarely require treatment discontinuation
In severe cases, it can lead to anemia and neurological problems
